IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients von Nishio, Makoto, Saito, Haruhiro, Goto, Koichi, Watanabe, Satoshi, Sueoka‐Aragane, Naoko, Okuma, Yusuke, Kasahara, Kazuo, Chikamori, Kenichi, Nakagawa, Yuki, Kawakami, Tomohisa

Volltext

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer von Hotta, Katsuyuki, Aoe, Keisuke, Kozuki, Toshiyuki, Ohashi, Kadoaki, Ninomiya, Kiichiro, Ichihara, Eiki, Kubo, Toshio, Ninomiya, Takashi, Chikamori, Kenichi, Harada, Daijiro, Nogami, Naoyuki, Hirata, Taizo, Hinotsu, Shiro, Toyooka, Shinichi, Kiura, Katsuyuki

Volltext

Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicent... von Tamura, Tomoki, Ninomiya, Kiichiro, Kubo, Toshio, Kuyama, Shoichi, Tachibana, Sayaka, Inoue, Koji, Chikamori, Kenichi, Kudo, Kenichiro, Ochi, Nobuaki, Harada, Daijiro, Maeda, Yoshinobu, Kiura, Katsuyuki

Volltext

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer von Yamamoto, Noboru, Goto, Koichi, Nishio, Makoto, Chikamori, Kenichi, Hida, Toyoaki, Maemondo, Makoto, Katakami, Nobuyuki, Kozuki, Toshiyuki, Yoshioka, Hiroshige, Seto, Takashi, Tajima, Kosei, Tamura, Tomohide

Volltext

Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tubercu... von Ogata, Yoshiko, Aoe, Keisuke, Hiraki, Akio, Murakami, Kazuo, Kishino, Daizo, Chikamori, Kenichi, Maeda, Tadashi, Ueoka, Hiroshi, Kiura, Katsuyuki, Tanimoto, Mitsune

Volltext

Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin von Vaziri, Susan A.J., Hill, Jason, Chikamori, Kenichi, Grabowski, Dale R., Takigawa, Nagio, Chawla-Sarkar, Mamta, Rybicki, Lisa R., Gudkov, Andrei V., Mekhail, Tarek, Bukowski, Ronald M., Ganapathi, Mahrukh K., Ganapathi, Ram

Volltext

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Canc... von Ichihara, Eiki, Hotta, Katsuyuki, Nogami, Naoyuki, Kuyama, Shoichi, Kishino, Daizo, Fujii, Masanori, Kozuki, Toshiyuki, Tabata, Masahiro, Harada, Daijiro, Chikamori, Kenichi, Aoe, Keisuke, Ueoka, Hiroshi, Hosokawa, Shinobu, Bessho, Akihiro, Hisamoto-Sato, Akiko, Kubo, Toshio, Oze, Isao, Takigawa, Nagio, Tanimoto, Mitsune, Kiura, Katsuyuki

Volltext

Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD von Chikamori, Kenichi, Maeda, Tadashi, Sakamoto, Kenji, Aoe, Keisuke, Utsunomiya, Toshiaki, Murata, Yoriyuki, Nakanishi, Masamoto, Kamei, Haruhito

Volltext

P1-073Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD von Chikamori, Kenichi, Maeda, Tadashi, Sakamoto, Kenji, Aoe, Keisuke, Utsunomiya, Toshiaki, Murata, Yoriyuki, Nakanishi, Masamoto, Kamei, Haruhito

Volltext

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor ( EGFR ) mutation-positive advanced non-small... von Goto, Koichi, Nishio, Makoto, Yamamoto, Noboru, Chikamori, Kenichi, Hida, Toyoaki, Maemondo, Makoto, Katakami, Nobuyuki, Kozuki, Toshiyuki, Yoshioka, Hiroshige, Seto, Takashi, Fukuyama, Tamaki, Tamura, Tomohide

Volltext

Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study von Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Inoue, Takako, Sakamoto, Tomohiro, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Takeoka, Hiroaki, Chikamori, Kenichi, Shinagawa, Naofumi, Tanaka, Hiroshi, Horii, Eisuke, Adrian, Svenja, Bruns, Rolf, Johne, Andreas, Paik, Paul K., Sakai, Hiroshi

Volltext

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations von Yoh, Kiyotaka, Azuma, Koichi, Hayashi, Hidetoshi, Nishio, Makoto, Chikamori, Kenichi, Ichihara, Eiki, Watanabe, Yasutaka, Asato, Takayuki, Kitagawa, Tadayuki, Fram, Robert J., Ohe, Yuichiro

Volltext

MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp von Morise, Masahiro, Sakai, Hiroshi, Kato, Terufumi, Tokito, Takaaki, Takeda, Masayuki, Tanaka, Hiroshi, Chikamori, Kenichi, Daga, Haruko, Kijima, Takashi, Ohashi, Kadoaki, Karachaliou, Niki, Ellers-Lenz, Barbara, Wu, Yi-Long

Volltext

PS1-2 CLIP1-LTK: a novel target in non-small cell lung cancer von Izumi, Hiroki, Matsumoto, Shingo, Mori, Shunta, Hayashi, Kumiko, Watanabe, Kana, Fukuhara, Tatsuro, Shibata, Yuji, Yoh, Kiyotaka, Morise, Masahiro, Toyozawa, Ryo, Chikamori, Kenichi, Miyamoto, Shingo, Asano, Shuichi, Shingyoji, Masato, Nakao, Mika, Azuma, Koichi, Niho, Seiji, Ishii, Genichiro, Kobayashi, S. Susumu, Goto, Koichi

Volltext

O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION) von Morise, Masahiro, Sakai, Hiroshi, Kato, Terufumi, Matsumoto, Shingo, Kumagai, Toru, Sakamoto, Tomohiro, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Takeoka, Hiroaki, Chikamori, Kenichi, Shinagawa, Naofumi, Tanaka, Hiroshi, Hirashima, Tomonori, Eggleton, S Peter, Bruns, Rolf, Otto, Gordon, Paik, Paul

Volltext

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint von Kozuki, Toshiyuki, Chikamori, Kenichi, Surleac, Marius D, Micluta, Marius A, Petrescu, Andrei J, Norris, Eric J, Elson, Paul, Hoeltge, Gerald A, Grabowski, Dale R, Porter, Andrew C G, Ganapathi, Ram N, Ganapathi, Mahrukh K

Volltext

Synergistic Effects of Topoisomerase I Inhibitor, 7-ethyl-10-hydroxycamptothecin, and Irradiation in a Cisplatin-resistant Human Small Cell Lung Cancer Cell Line von KOHARA, Hiroyuki, TABATA, Masahiro, KIURA, Katsuyuki, UEOKA, Hiroshi, KAWATA, Kazuhiko, CHIKAMORI, Masakazu, AOE, Keisuke, CHIKAMORI, Kenichi, MATSUSHITA, Akio, HARADA, Mine

Volltext

A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild type EGFR (OLCSG1202) von Bessho, Akihiro, Ochi, Nobuaki, Kuyama, Shoichi, Fujimoto, Nobukazu, Umeno, Takahiro, Ninomiya, Kiichiro, Ikeda, Genyo, Harada, Daijiro, Kishino, Daizo, Hosokawa, Shinobu, Chikamori, Kenichi, Nogami, Naoyuki, Harita, Shingo, Ueoka, Hiroshi, Hotta, Katsuyuki, Takigawa, Nagio, Tanimoto, Mitsune, Kiura, Katsuyuki

Volltext

Impact of concomitant use of anti-acid agents on efficacy of gefitinib in EGFR-mutant non-small-cell lung cancer (NSCLC) von Chikamori, Kenichi, Aoe, Keisuke, Maeda, Tadashi, Kishino, Daizo, Oishi, Keiji, Hotta, Katsuyuki, Matsumoto, Tsuneo, Ueoka, Hiroshi

Volltext

Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer von Nishio, Makoto, Goto, Koichi, Chikamori, Kenichi, Hida, Toyoaki, Katakami, Nobuyuki, Maemondo, Makoto, Ohishi, Norihisa, Tamura, Tomohide

Volltext